GlassScriptPhysician profile
Kenneth Holling
NPI 1396737516
$2,441.60
in general payments reported to CMS, 2019-2025
28 companies · $495 in 2025
The $495 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $56.68 · 2021: $223 · 2022: $411 · 2023: $563 · 2024: $445 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.45 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $320.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $230.22 | 2021-2025 | Breztri, Tezspire |
| Novo Nordisk INC | $221.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insmed, INC. | $191.30 | 2020-2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $144.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $140.25 | 2022-2023 | |
| Genzyme Corporation | $94.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.94 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.45 | 2023-2025 | Xifaxan |
| Abbott Laboratories | $62.06 | 2021-2025 | Freestyle Libre 3 |
| Philips North America LLC | $54.35 | 2019 | |
| United Therapeutics Corporation | $48.14 | 2021 | |
| Verona Pharma, INC. | $41.25 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $40.38 | 2023 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37.40 | 2024 | Dupixent |
| Inogen, INC. | $32.26 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.75 | 2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $21.22 | 2023 | Nuzyra |
| Advanced Respiratory, INC | $20.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.50 | 2022 | |
| Dexcom, INC. | $20.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.24 | 2021 | |
| Merck Sharp & Dohme LLC | $18.15 | 2019 | |
| Seqirus USA INC | $17.01 | 2019 | |
| Pfizer INC. | $16.78 | 2021 | |
| Inspire Medical Systems, INC. | $16.73 | 2025 | Inspire |
| Amgen INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Holling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.